OBJECTIVE: We compared outcomes and adverse events of thrombectomy versus medical management in acute ischemic stroke (AIS) patients with baseline large infarct core. METHODS: We searched Ovid MEDLINE(R) ALL, Cochrane Library Clinical Controlled Trials and EMBASE from inception to January 2021 for studies comparing thrombectomy and medical management alone in AIS patients who had ASPECTS <=7 or ischemic core volume >=50 ml. Imaging modalities to valuate ASPECTS and core volume were without restriction. The functional outcome was measured by mRS (modified Rankin Scale) score 0-2 at 90 days or discharge. The safety end point included the rates of mortality and sICH (symptomatic intracranial hemorrhage) or PH2 (parenchymal hematoma type 2). RESULTS: Fourteen studies with a total of 2547 patients (thrombectomy n = [1197]; medical care alone [n = 1350]) fulfilled our criteria. As for patients with low ASPECTS, pooled results indicated a higher odds of good functional outcome (OR = 3.47; 95% CI 1.99 to 6.07; P < 0.0001, I2=66%) and a lower risk of mortality (OR = 0.62; 95% CI 0.46 to 0.83; P = 0.001, I2=32%) in thrombectomy group compared with no thrombectomy group, but the risk of sICH or PH2 did not differ between two groups. As for patients with large core volume, both functional outcome and safety end point between two groups showed no statistically significant difference. CONCLUSION: Thrombectomy remained safe and effective by careful selection in patients with low ASPECTS. More studies were warranted to explore contraindications for mechanical thrombectomy in AIS patients, especially in patients with large core volume.
OBJECTIVE: We compared outcomes and adverse events of thrombectomy versus medical management in acute ischemic stroke (AIS) patients with baseline large infarct core. METHODS: We searched Ovid MEDLINE(R) ALL, Cochrane Library Clinical Controlled Trials and EMBASE from inception to January 2021 for studies comparing thrombectomy and medical management alone in AIS patients who had ASPECTS <=7 or ischemic core volume >=50 ml. Imaging modalities to valuate ASPECTS and core volume were without restriction. The functional outcome was measured by mRS (modified Rankin Scale) score 0-2 at 90 days or discharge. The safety end point included the rates of mortality and sICH (symptomatic intracranial hemorrhage) or PH2 (parenchymal hematoma type 2). RESULTS: Fourteen studies with a total of 2547 patients (thrombectomy n = [1197]; medical care alone [n = 1350]) fulfilled our criteria. As for patients with low ASPECTS, pooled results indicated a higher odds of good functional outcome (OR = 3.47; 95% CI 1.99 to 6.07; P < 0.0001, I2=66%) and a lower risk of mortality (OR = 0.62; 95% CI 0.46 to 0.83; P = 0.001, I2=32%) in thrombectomy group compared with no thrombectomy group, but the risk of sICH or PH2 did not differ between two groups. As for patients with large core volume, both functional outcome and safety end point between two groups showed no statistically significant difference. CONCLUSION: Thrombectomy remained safe and effective by careful selection in patients with low ASPECTS. More studies were warranted to explore contraindications for mechanical thrombectomy in AIS patients, especially in patients with large core volume.
Entities:
Keywords:
Mechanical thrombectomy; infarct core; large ischemic core; meta-analysis
Authors: James E Siegler; Steven R Messé; Heidi Sucharew; Scott E Kasner; Tapan Mehta; Niraj Arora; Amy K Starosciak; Felipe De Los Rios La Rosa; Natasha R Barnhill; Akshitkumar M Mistry; Kishan Patel; Salman Assad; Amjad Tarboosh; Katarina Dakay; Jeff Wagner; Alicia Bennett; Bharathi Jagadeesan; Christopher Streib; Stewart A Weber; Rohan Chitale; John J Volpi; Stephan A Mayer; Shadi Yaghi; Mahesh V Jayaraman; Pooja Khatri; Eva A Mistry Journal: J Neuroimaging Date: 2019-11-24 Impact factor: 2.486
Authors: K Wasser; P Papanagiotou; F Brunner; H Hildebrandt; M Winterhalter; C Roth; A Kastrup Journal: Eur J Neurol Date: 2016-07-14 Impact factor: 6.089
Authors: Bruce C V Campbell; Peter J Mitchell; Timothy J Kleinig; Helen M Dewey; Leonid Churilov; Nawaf Yassi; Bernard Yan; Richard J Dowling; Mark W Parsons; Thomas J Oxley; Teddy Y Wu; Mark Brooks; Marion A Simpson; Ferdinand Miteff; Christopher R Levi; Martin Krause; Timothy J Harrington; Kenneth C Faulder; Brendan S Steinfort; Miriam Priglinger; Timothy Ang; Rebecca Scroop; P Alan Barber; Ben McGuinness; Tissa Wijeratne; Thanh G Phan; Winston Chong; Ronil V Chandra; Christopher F Bladin; Monica Badve; Henry Rice; Laetitia de Villiers; Henry Ma; Patricia M Desmond; Geoffrey A Donnan; Stephen M Davis Journal: N Engl J Med Date: 2015-02-11 Impact factor: 91.245
Authors: Luis San Román; Bijoy K Menon; Jordi Blasco; María Hernández-Pérez; Antoni Dávalos; Charles B L M Majoie; Bruce C V Campbell; Francis Guillemin; Hester Lingsma; René Anxionnat; Jonathan Epstein; Jeffrey L Saver; Henk Marquering; John H Wong; Demetrius Lopes; Gernot Reimann; Hubert Desal; Diederik W J Dippel; Shelagh Coutts; Richard du Mesnil de Rochemont; Dileep Yavagal; Jean Christophe Ferre; Yvo B W E M Roos; David S Liebeskind; Robert Lenthall; Carlos Molina; Fahad S Al Ajlan; Vivek Reddy; Dar Dowlatshahi; Nader-Antoine Sourour; Catherine Oppenheim; Alim P Mitha; Stephen M Davis; Christian Weimar; Robert J van Oostenbrugge; Erik Cobo; Timothy J Kleinig; Geoffrey A Donnan; Aad van der Lugt; Andrew M Demchuk; Olvert A Berkhemer; Anna M M Boers; Gary A Ford; Keith W Muir; B Scott Brown; Tudor Jovin; Wim H van Zwam; Peter J Mitchell; Michael D Hill; Phil White; Serge Bracard; Mayank Goyal Journal: Lancet Neurol Date: 2018-09-18 Impact factor: 44.182
Authors: Jelle Demeestere; Carlos Garcia-Esperon; Pablo Garcia-Bermejo; Fouke Ombelet; Patrick McElduff; Andrew Bivard; Mark Parsons; Christopher Levi Journal: Neurology Date: 2017-05-17 Impact factor: 9.910